Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease

被引:151
作者
Sun, YX
Minthon, L
Wallmark, A
Warkentin, S
Blennow, K
Janciauskiene, S
机构
[1] Malmo Univ Hosp, Dept Med, Malmo, Sweden
[2] Malmo Univ Hosp, Neuropsychiat Clin, Dept Psychiat, Malmo, Sweden
[3] Univ Gothenburg, Dept Clin Neurosci, Unit Neurochem, Gothenburg, Sweden
关键词
Alzheimer's disease; amyloid-beta peptide; alpha(1)-antichymotrypsin; alpha(1)-antitrypsin; inflammation; pro-inflammatory cytokines; monocyte chemoattractant protein-1; oxidised low-density lipoproteins;
D O I
10.1159/000071001
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
It has been suggested that a number of molecules associated with inflammation are involved in the pathogenesis of Alzheimer's disease (AD). We measured the levels of alpha(1)-antichymotrypsin (ACT), alpha(1)-antitrypsin (AAT), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and oxidised low-density lipoprotein (oxLDL) in matched cerebrospinal fluid (CSF) and plasma of 141 patients with probable AD. We found a significant relationship between CSF and plasma levels of ACT (r = 0.4, p < 0.001), IL-6 (r = 0.74, p < 0.001), MCP-1 (r = 0.71, p < 0.001), and a borderline relationship between CSF and plasma oxLDL (r = 0.22, p < 0.05). In addition, linear regression analysis revealed a positive correlation between levels of CSF-ACT and oxLDL (p < 0.001), but an inverse relation between levels of CSF ACT, CSF AAT and MCP-1 (p < 0.001). A significant correlation was also found between levels of CSF ACT, oxLDL and the ratio of CSF to serum albumin, which is used as a measure of the blood-brain barrier function. Our data extend previous reports regarding the inflammatory markers in the plasma and CSF of patients with AD and provide good evidence that levels of ACT, IL-6, MCP-1 and oxLDL in plasma and CSF might be candidates as biomarkers for monitoring the inflammatory process in AD. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:136 / 144
页数:9
相关论文
共 61 条
[1]   APOE genotype:: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease [J].
Aerssens, J ;
Raeymaekers, P ;
Lilienfeld, S ;
Geerts, H ;
Konings, F ;
Parys, W .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (02) :69-77
[2]   Inflammation and Alzheimer's disease [J].
Akiyama, H ;
Barger, S ;
Barnum, S ;
Bradt, B ;
Bauer, J ;
Cole, GM ;
Cooper, NR ;
Eikelenboom, P ;
Emmerling, M ;
Fiebich, BL ;
Finch, CE ;
Frautschy, S ;
Griffin, WST ;
Hampel, H ;
Hull, M ;
Landreth, G ;
Lue, LF ;
Mrak, R ;
Mackenzie, IR ;
McGeer, PL ;
O'Banion, MK ;
Pachter, J ;
Pasinetti, G ;
Plata-Salaman, C ;
Rogers, J ;
Rydel, R ;
Shen, Y ;
Streit, W ;
Strohmeyer, R ;
Tooyoma, I ;
Van Muiswinkel, FL ;
Veerhuis, R ;
Walker, D ;
Webster, S ;
Wegrzyniak, B ;
Wenk, G ;
Wyss-Coray, T .
NEUROBIOLOGY OF AGING, 2000, 21 (03) :383-421
[3]   Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].
Andreasen, N ;
Hesse, C ;
Davidsson, P ;
Minthon, L ;
Wallin, A ;
Winblad, B ;
Vanderstichele, H ;
Vanmechelen, E ;
Blennow, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680
[4]   Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease [J].
Bhojak, TJ ;
DeKosky, ST ;
Ganguli, M ;
Kamboh, MI .
NEUROSCIENCE LETTERS, 2000, 288 (01) :21-24
[5]   PROTEIN-ANALYSIS IN CEREBROSPINAL-FLUID .2. REFERENCE VALUES DERIVED FROM HEALTHY-INDIVIDUALS 18-88 YEARS OF AGE [J].
BLENNOW, K ;
FREDMAN, P ;
WALLIN, A ;
GOTTFRIES, CG ;
KARLSSON, I ;
LANGSTROM, G ;
SKOOG, I ;
SVENNERHOLM, L ;
WIKKELSO, C .
EUROPEAN NEUROLOGY, 1993, 33 (02) :129-133
[6]   tau protein in cerebrospinal fluid - A biochemical marker for axonal degeneration in Alzheimer disease? [J].
Blennow, K ;
Wallin, A ;
Agren, H ;
Spenger, C ;
Siegfried, J ;
Vanmechelen, E .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 26 (03) :231-245
[7]   Risk of Alzheimer disease with the ε4 allele for apolipoprotein E in a population-based study of men aged 62-73 years [J].
Breitner, JCS ;
Jarvik, GP ;
Plassman, BL ;
Saunders, AM ;
Welsh, KA .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (01) :40-44
[8]   Vascular endothelium is a site of free radical production and inflammation in areas of neuronal loss in thiamine-deficient brain [J].
Calingasan, NY ;
Gibson, GE .
VASCULAR FACTORS IN ALZHEIMER'S DISEASE, 2000, 903 :353-356
[9]   Identification of oxidized plasma proteins in Alzheimer's disease [J].
Choi, JG ;
Malakowsky, CA ;
Talent, JM ;
Conrad, CC ;
Gracy, RW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (05) :1566-1570
[10]   Oxidative stress and Alzheimer disease [J].
Christen, Y .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2000, 71 (02) :621S-629S